Non-Exudative Macular Degeneration and Management
Non-exudative, age-related macular degeneration, which accounts for 85 percent of AMD cases, includes a spectrum of macular pathology. In its most mild form, the macula possesses few Drusen or retinal pigmentary epithelial (RPE) change with no visual disability. At the other end of this spectrum, the macula is affected by large areas of RPE atrophy, with devastating loss of central vision.
This chapter examines normal and pathologic changes in the macular leading to non-exudative macular degeneration, and reviews the clinical trials that have been performed on patients with this disease.
Keywordsmacular degeneration Drusen AREDS PTAMD CAPT CNVPT rheophoresis MIRA laser AMD
- 1.National Advisory Eye Council (1993) Vision research: a national plan 1994–1998. NIH publication no. 93–3186. US Department of Health and Human Services, Bethesda, MDGoogle Scholar
- 3.Klein R, Klein BEK, Linton KLP (1992) Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmol 99:933–43Google Scholar
- 5.Age-Related Eye Disease Study Research Group. (2001) A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 119(10):1417–36Google Scholar